Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

YIjia Li

Showing results (191-200 of 216) with videos related to

Pageof 22
Sort By:
Arxiv|July 30, 2025
A foundation model for human-AI collaboration in medical literature miningZifeng Wang, Lang Cao, Qiao Jin, et al.
Nature Communications|September 24, 2025
A foundation model for human-AI collaboration in medical literature miningZifeng Wang, Lang Cao, Qiao Jin, et al.
JCI Insight|September 9, 2025
Virologic characteristics of SARS-CoV-2 infection across evolving Omicron subvariantsJulie Boucau, Owen T Glover, Caitlin Marino, et al.
Annals of Internal Medicine|November 13, 2023
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational StudyGregory E Edelstein, Julie Boucau, Rockib Uddin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 10, 2023
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapyGregory E Edelstein, Julie Boucau, Rockib Uddin, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical TrialKara W Chew, Carlee Moser, Eric S Daar, et al.
Journal of Virology|February 4, 2025
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2025
Humoral Immunity Against Orthopoxvirus in Vaccinated and Unvaccinated Individuals during 2022 Mpox OutbreakYijia Li, Michael B Townsend, Shanshan Li, et al.
JCI Insight|February 8, 2024
Predictors of HIV rebound differ by timing of antiretroviral therapy initiationJonathan Z Li, Meghan Melberg, Autumn Kittilson, et al.
Pageof 22

Showing results (191-200 of 216) with videos related to

Sort By:
Pageof 22
Arxiv|July 30, 2025
A foundation model for human-AI collaboration in medical literature miningZifeng Wang, Lang Cao, Qiao Jin, et al.
Nature Communications|September 24, 2025
A foundation model for human-AI collaboration in medical literature miningZifeng Wang, Lang Cao, Qiao Jin, et al.
JCI Insight|September 9, 2025
Virologic characteristics of SARS-CoV-2 infection across evolving Omicron subvariantsJulie Boucau, Owen T Glover, Caitlin Marino, et al.
Annals of Internal Medicine|November 13, 2023
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational StudyGregory E Edelstein, Julie Boucau, Rockib Uddin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 10, 2023
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapyGregory E Edelstein, Julie Boucau, Rockib Uddin, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical TrialKara W Chew, Carlee Moser, Eric S Daar, et al.
Journal of Virology|February 4, 2025
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2025
Humoral Immunity Against Orthopoxvirus in Vaccinated and Unvaccinated Individuals during 2022 Mpox OutbreakYijia Li, Michael B Townsend, Shanshan Li, et al.
JCI Insight|February 8, 2024
Predictors of HIV rebound differ by timing of antiretroviral therapy initiationJonathan Z Li, Meghan Melberg, Autumn Kittilson, et al.
Pageof 22